News

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full-year revenue guidance of $766 million at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 13.6% above analysts’ consensus estimates.

(Bloomberg) -- The world’s oil traders descended on London this week, and in the bars and hotels of the city’s Mayfair district they were getting re-accustomed to checking their phones for what Donald Trump might say next. Most Read from BloombergCuts to Section 8 Housing Assistance Loom Amid HUD UncertaintyThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC Office Buildings See Resurgence as Investors Pile Into Bond

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 18.4% year on year to $730.5 million. The company’s full-year revenue guidance of $3.05 billion at the midpoint came in 4.5% above analysts’ estimates. Its non-GAAP profit of $0.12 per share was 21.1% below analysts’ consensus estimates.

(Reuters) -Wall Street ended higher on Friday after a choppy trading session, with Dell Technologies dipping and other tech stocks climbing after a meeting between the U.S. President Donald Trump and Ukrainian counterpart Volodymyr Zelenskiy ended in disaster. Zelenskiy and Trump traded verbal blows at the White House before the world's media. This created fresh uncertainty over Ukraine's war with Russia for investors already worried about sticky U.S. inflation and a tepid economy.

NEW YORK (Reuters) -Federal Reserve Bank of Cleveland President Beth Hammack reckons the U.S. central bank can keep steadily shrinking its balance sheet through a period of uncertain government finances, while noting she is disinclined to support an interest rate hike even if inflation pressures do not retreat quickly enough. Hammack said her "baseline preference" is that the Fed presses forward with the balance sheet drawdown commonly referred to as quantitative tightening, or QT, while the government sorts out its spending plans and adjusts the debt ceiling to facilitate its borrowing needs. Once that is resolved, the Fed can use temporary bond repurchases, or repos, if needed, "to put more (liquidity) back in the system until you figure out" the market's needs, Hammack said in an interview with Reuters on Thursday.

Whether Adidas can win more American shoppers from market leader Nike will be key to its continued success this year, investors and analysts said, as the German brand looks for new sources of growth beyond its Samba and Gazelle sneakers. Uncertainty over whether consumer demand in China will recover has driven many brands, including in the luxury sector, to focus more on U.S. shoppers as a growth driver for 2025. Chief Executive Bjorn Gulden has turned Adidas around since the brand cut ties with rapper Ye and scrapped its lucrative Yeezy sneaker line in October 2022.